Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists. 2009

Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
Dipartimento di Scienze Farmaceutiche, Universita di Pisa, Via Bonanno 6, 56126 Pisa, Italy.

The CB(2) receptor activation can be exploited for the treatment of diseases such as chronic pain and tumors of immune origin, devoid of psychotropic activity. On the basis of our already reported 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives, new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the human CB(1) and CB(2) cannabinoid receptors. Some of the reported compounds showed a subnanomolar CB(2) affinity with a CB(1)/CB(2) selectivity ratio greater than 200 (compounds 6, 12, cis-12, 13, and cis-13). Further studies revealed that compound 12, which presented benzyl and carboxy-4-methylcyclohexylamide substituents bound in the 1 and 3 positions, exerted a CB(2)-mediated inhibitory action on immunological human basophil activation. On the human T cell leukemia line Jurkat the same derivative induced a concentration-dependent decrease of cell viability. The obtained results suggest that 1,8-naphthyridin-2(1H)-on-3-carboxamides represent a new scaffold very suitable for the development of new promising CB(2) agonists.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009287 Naphthyridines A group of two-ring heterocyclic compounds consisting of a NAPHTHALENES double ring in which two carbon atoms, one per each ring, are replaced with nitrogens.
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
December 2018, MedChemComm,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
February 2013, Journal of medicinal chemistry,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
January 2006, Journal of medicinal chemistry,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
December 2022, ACS medicinal chemistry letters,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
November 1999, European journal of medicinal chemistry,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
April 1994, Biological & pharmaceutical bulletin,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
January 2022, RSC advances,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
May 2004, Bioorganic & medicinal chemistry,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
September 2007, Bioorganic & medicinal chemistry letters,
Clementina Manera, and Giuseppe Saccomanni, and Barbara Adinolfi, and Veronica Benetti, and Alessia Ligresti, and Maria Grazia Cascio, and Tiziano Tuccinardi, and Valentina Lucchesi, and Adriano Martinelli, and Paola Nieri, and Emanuela Masini, and Vincenzo Di Marzo, and Pier Luigi Ferrarini
March 2008, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!